Multi-Center Study of Aflibercept Therapy for Neovascular Age-Related Macular Degeneration Using Trreat and Extend Strategy

Multi-Center Study of Aflibercept Therapy for Neovascular Age-Related Macular Degeneration Using Trreat and Extend Strategy - Treat & Extend Stratedy with Aflibercept for AMD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016152

Enrollment

200

Registered

2015-01-07

Start date

2015-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular age-related macular degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 20-year-old or older 2. Neovascular age-related macular degeneration with exudative changes detected by optical coherence tomography 3. No previous treatment history for age-related macular degeneration 4. Agreement with informed consent

Exclusion criteria

Exclusion criteria: 1. Local Steroid Therapy within 3 momths 2. Previous history of anti-VEGF treatments 3. Past history of photodynamic therapy 4. Severe cataract 5. Local or systemic infection 6. Hisrory of uveitis 7. Apahakic eyes 8. Uncontrolled hypertension 9. Cerebrovascular or cardiac vascular accident within 6 months 10. Renal failure requiring dyalisis 11. Allegy for fluorescsin and indocyaningreen dye 12. Pregnancy or lactating 13. Other conditions that the principal investigator points out

Design outcomes

Primary

Measure	Time frame
The changes in visual acuity during 1-year after aflibercept therapy	—

Countries

Japan

Contacts

Public ContactHideki Koizumi

Tokyo Women's Medical University Ophthalmology

koizumi.hideki@twmu.ac.jp03-3353-8111

Outcome results